Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol

Autor: Sydes, M R, Spears, M R, Mason, M D, Clarke, N W, Dearnaley, D P, de Bono, J S, Attard, G, Chowdhury, S, Cross, W, Gillessen, S, Malik, Z I, Jones, R, Parker, C C, Ritchie, A W S, Russell, J M, Millman, R, Matheson, D, Amos, C, Gilson, C, Birtle, A, Brock, S, Capaldi, L, Chakraborti, P, Choudhury, A, Evans, L, Ford, D, Gale, J, Gibbs, S, Gilbert, D C, Hughes, R, McLaren, D, Lester, J F, Nikapota, A, O’Sullivan, J, Parikh, O, Peedell, C, Protheroe, A, Rudman, S M, Shaffer, R, Sheehan, D, Simms, M, Srihari, N, Strebel, R, Sundar, S, Tolan, S, Tsang, D, Varughese, M, Wagstaff, J, Parmar, M K B, James, N D

Publikováno v: Annals of Oncology
Sydes, M R, Spears, M R, Mason, M D, Clarke, N W, Dearnaley, D P, de Bono, J S, Attard, G, Chowdhury, S, Cross, B, Gillessen, S, Malik, Z, Jones, R, Parker, C, Ritchie, A W S, Russell, J M, Millman, R, Matheson, D, Amos, C, Gilson, C, Birtle, A, Brock, S, Capaldi, L, Chakraborti, P, Choudhury, A, Evans, L, Ford, D, Gale, J, Gibbs, S, Gilbert, D, Hughes, R, McLaren, D, Lester, J, Nikapota, A, O'Sullivan, J, Parikh, O, Peedell, C, Protheroe, A, Rudman, S M, Shaffer, R, Sheehan, D, Simms, M, Srihari, N, Strebel, R, Sundar, S, Tolan, S, Tsang, D, Varughese, M, Wagstaff, J, Parmar, M K B & James, N D 2018, ' Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol ', Annals of Oncology . https://doi.org/10.1093/annonc/mdy072
Sydes, M R, Spears, M, Mason, M, Clarke, N, Dearnaley, D P, de Bono, J, Attard, G, Chowdhury, S, Cross, W, Gillessen Sommer, S, Malik, Z, Jones, R, Parker, C, Ritchie, A W S, Russell, J M, Millman, R, Matheson, D, Amos, C, Gilson, C, Birtle, A, Brock, S, Capaldi, L, Chakraborti, P, Choudhury, A, Evans, L, Ford, D, Gale, J, Gibbs, S, Gilbert, D C, Hughes, R, McLaren, D, Lester, J, Nikapota, A, O'Sullivan, J, Parikh, O, Peedell, C, Protheroe, A, Rudman, S, Shaffer, R, Sheehan, D, Simms, M, Srihari, N, Strebel, R, Sundar, S, Tolan, S, Tsang, D, Varughese, M, Wagstaff, J, Parmar, M K B & James, N 2018, ' Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer : directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol ', Annals of Oncology, vol. 29, no. 5, pp. 1235-1248 . https://doi.org/10.1093/annonc/mdy072

Background Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival in systemic therapy for advanced or metastatic prostate cancer: evaluation of drug efficacy: a multi-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::4ec65067a6609dcbd43d7690a573f6a6